All In Biotech

Drug Trial Radar · NCT04617028

Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

A Randomized, Double-blind, Double-simulated, Parallel-controlled, Multicenter Phase III Study Evaluating the Efficacy and Safety of Jaktinib Versus Hydroxycarbamide in Patients With Intermediate-2 or High-risk Myelofibrosis

Last checked: Nov 19, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Feb 5, 2021

Primary completion

Oct 18, 2023

Study completion Oct 18, 2023

Sponsor

Sponsor type
Industry
First posted
Nov 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to determine the efficacy of Jaktinib versus Hydroxycarbamid in participants with Intermediate-2 or High-risk myelofibrosis

Conditions

  • Myelofibrosis

Interventions

  • JaktinibDrug

    Jaktinib Hydrochloride Tablets administered orally twice daily

  • Placebo to match HydroxycarbamideDrug

    Placebo to match Hydroxycarbamide Tablets administered orally twice daily

  • Hydroxycarbamide TabletsDrug

    Hydroxycarbamide Tablets administered orally twice daily

  • Placebo to match JaktinibDrug

    Placebo to match Jaktinib Tablets administered orally twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Splenic response rate at Week 24Time frame: Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Medical School of Zhejiang University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.